Stocktoria
Oscar Health, Inc. OSCR
Oscar Health, Inc. (OSCR) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $11.7B at a -3.8% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-06-10 | Barclays | Overweight (up) |
| 2026-05-26 | Barclays | Equal-Weight (main) |
| 2026-05-07 | UBS | Neutral (main) |
| 2026-05-07 | Barclays | Equal-Weight (main) |
| 2026-05-07 | Baird | Neutral (main) |
| 2026-05-06 | Wolfe Research | Peer Perform (init) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Finance, Insurance & Real Estate · percentile among 1129 companies
Percentile vs other Finance, Insurance & Real Estate companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | -0.039 |
| Retained earnings / assets | -0.521 |
| EBIT / assets | -0.063 |
| Equity / liabilities | 0.183 |
Sector peers · similar-size Finance, Insurance & Real Estate companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| OSCR | Oscar Health, Inc. | 4/9 | -2.18 | — | +27.5% |
| ALHC | Alignment Healthcare, Inc. | 5/9 | -0.35 | — | +46.1% |
| CLOV | CLOVER HEALTH INVESTMENTS, CORP. /DE | 2/9 | -12.26 | — | +40.3% |
| TRUP | TRUPANION, INC. | 2/9 | 2.14 | — | +11.9% |
| MOH | MOLINA HEALTHCARE, INC. | 4/9 | 3.6 | 25.4 | +11.7% |
| HUM | HUMANA INC | 5/9 | 5.1 | 38.8 | +10.1% |
| CNC | CENTENE CORP | 4/9 | 0.38 | — | +19.4% |
All Finance, Insurance & Real Estate companies →
About Oscar Health, Inc.
Oscar Health, Inc. operates as a healthcare technology company in the United States. The company offers health plans to individuals, families, employees, and small group markets. It also provides +Oscar platform that power others throughout the healthcare system; Campaign Builder platform, an engagement and recommendation platform for providers and payors; and reinsurance products. In addition, the company offers brokerage services and enrollment platform for brokers and consumers to shop, buy, and enroll in medical and supplemental health products. The company was formerly known as Mulberry Health Inc. and changed its name to Oscar Health, Inc. in January 2021. Oscar Health, Inc. was incorporated in 2012 and is headquartered in New York, New York.
FAQ
Is OSCR financially healthy?
Oscar Health, Inc.'s Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does OSCR pay a dividend?
No, Oscar Health, Inc. does not currently pay a dividend.
How profitable is OSCR?
In FY2025, Oscar Health, Inc. had a net margin of -3.8% and a return on equity of -45.2%.
What is the analyst price target for OSCR?
The average Wall-Street price target for Oscar Health, Inc. is $22.60, about 23.7% below the recent price, from 10 analysts (consensus: hold).
Is OSCR a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Oscar Health, Inc.: a Piotroski F-score of 4/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.